Compare Novavax Inc (NVAX) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Schwab US Large Cap Growth ETF — how do they compare? Novavax Inc trades at $12.64 (market cap $1.82B), while Schwab US Large Cap Growth ETF trades at $36.71 (market cap $65.01B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 35.7× Novavax Inc's market cap, and Schwab US Large Cap Growth ETF is more actively traded (8,554,399 versus 6,198,505). Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| NVAX | SCHG | |
|---|---|---|
Market Cap | $1.82B | $65.01B |
Volume | 6,198,505 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $12.56 | $36.93 |
52-Week Low | $6.22 | $28.10 |
Typical Hold Time | 59 Days | 50 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
SCHG (Schwab U.S. Large-Cap Growth ETF) trades at $36.60, down 0.73% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite a recent position reduction by Corient Private Wealth. Recent news highlights SCHG's low-cost advantage and growth-focused strategy, though concentration in top holdings presents both opportunity and risk.
The outlook for SCHG remains positive given its exposure to large-cap growth stocks and cost efficiency, though investors should monitor concentration risks in top holdings and broader market volatility. The ETF's historical performance suggests potential for long-term growth, but current valuation levels warrant careful assessment relative to alternatives like GARP strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
